Supplementary Materials

Supplementary Material for:

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

Adel Samson,* Karen J. Scott, David Taggart, Emma J. West, Erica Wilson, Gerard J. Nuovo, Simon Thomson, Robert Corns, Ryan K. Mathew, Martin J. Fuller, Timothy J. Kottke, Jill M. Thompson, Elizabeth J. Ilett, Julia V. Cockle, Philip van Hille, Gnanamurthy Sivakumar, Euan S. Polson, Samantha J. Turnbull, Elizabeth S. Appleton, Gemma Migneco, Ailsa S. Rose, Matthew C. Coffey, Deborah A. Beirne, Fiona J. Collinson, Christy Ralph, D. Alan Anthoney, Christopher J. Twelves, Andrew J. Furness, Sergio A. Quezada, Heiko Wurdak, Fiona Errington-Mais, Hardev Pandha, Kevin J. Harrington, Peter J. Selby, Richard G. Vile, Stephen D. Griffin, Lucy F. Stead, Susan C. Short,* Alan A. Melcher*

*Corresponding author. Email: a.samson{at}leeds.ac.uk (A.S.); alan.melcher{at}icr.ac.uk (A.A.M.); s.c.short{at}leeds.ac.uk (S.C.S.)

Published 3 January 2018, Sci. Transl. Med. 10, eaam7577 (2018)
DOI: 10.1126/scitranslmed.aam7577

This PDF file includes:

  • Fig. S1. Selective intravenous delivery of reovirus to intracranial melanoma in immunocompetent mice.
  • Fig. S2. Reovirus carriage by WBC subsets and changes in serum IFN-α.
  • Fig. S3. Secondary antibody–only control immunogold-TEM images from trial patient brain tumors.
  • Fig. S4. Reovirus protein expression in endothelial cells.
  • Fig. S5. Negative controls for reovirus coexpression.
  • Fig. S6. Correlation of reovirus RNA/protein with time between infusion and surgery.
  • Fig. S7. CD68 tumor-infiltrating cells.
  • Fig. S8. Expression of cleaved caspase 3 and PD-L1 in brain tumor metastases after reovirus stimulation.
  • Fig. S9. In vitro expression of PD-L1 and PD-1 in human-derived cell lines and healthy donor PBMCs after reovirus stimulation.
  • Fig. S10. In vitro expression of PD-L1 on GBM1 cells after purified IFN or CM stimulation.
  • Table S1. Participant baseline clinical characteristics, grade 3 or 4 adverse events, and survival after reovirus infusion.
  • Table S2. Change in plasma inflammatory cytokines and chemokines after intravenous reovirus infusion.
  • Table S3. Presence of reovirus protein and RNA in resected brain tumors.
  • Table S4. Ki67, cleaved caspase 3, immune cell infiltration, and PD-1/PD-L1 expression in resected trial and control brain tumors.
  • Table S6. Enriched biological processes within genes differentially expressed between control and trial GBM tumors.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S5 RNA-seq expression data (provided as an Excel file).